ICMR-NIV will test gastroenteritis samples from GBS patients in Pune, where 152 cases have surged, to identify potential ...

Findings indicate a sharp drop in immunity after Omicron infection, stressing the necessity for updated vaccines to enhance ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

COVID-19, even in mild cases, is linked to changes in Alzheimer’s disease-related brain biomarkers comparable to four years ...

Hyderabad: According to experts and medical professionals, the incidence of Guillain-Barré syndrome (GBS) is currently ...

The following is a summary of “Identification of patient demographic, clinical, and SARS-CoV-2 genomic factors associated with severe COVID-19 using supervised machine learning: a retrospective ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer ...

Inc. today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). "We are pleased to see Abecma expansion in the third ...

The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...

A newly developed vaccine against a group of viruses including SARS-CoV-2 is producing promising results in mice, part of the ...

A view of the Institute of Child Health and Hospital for Children at Egmore in Chennai | Photo Credit: B. Velankanni Raj ...

New research showed some long COVID patients get symptom relief by taking an extended course of Paxlovid. Data are ...